@ Newsroom | SEBIO

Visioneering Technologies Successfully Raises $33.3 Million (AUD) in Fully Underwritten Initial Public Offering

Posted by on Mar 16, 2017 in Newsroom | 0 comments

ALPHARETTA, GA. – Visioneering Technologies, Inc. (VTI), a US-based medical device company engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue™ Multifocal 1 Day (NaturalVue MF) contact lenses, has successfully raised A$33.3 million following the close of its fully underwritten Initial Public Offer (IPO). The IPO was strongly supported by institutional and sophisticated investors in Australia and Asia. The IPO proceeds will provide capital as VTI broadens and accelerates its US launch of its NaturalVue Multifocal (MF) daily disposable contact lenses...

Read More

Amend Surgical Signs Exclusive License Agreement with University of Florida Research Foundation for Biomimetic Bone

Posted by on Mar 15, 2017 in Newsroom | 0 comments

ALACHUA, FL. – Amend Surgical, Inc. (Amend), a medical device company focused on enhancing the regenerative capacity of bone replacement products, announced today an exclusive agreement with The University of Florida Research Foundation (UFRF) to license patents for the development of Biomimetic Bone, a novel artificial bone substitute. While bone is a natural composite of collagen and hydroxyapatite, its nanostructure is not duplicated in any available bone substitutes. In natural bone, the collagen is intimately associated with crystals of hydroxyapatite, which form within nanoscopic...

Read More

NeoGenomics and Definiens Enter Into Agreement to Develop Novel Assays for Clinical Trials & Clinical Testing

Posted by on Mar 15, 2017 in Newsroom | 0 comments

FORT MEYERS, FL. – NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, and Definiens, the leader in Tissue Phenomics® solutions from biomarker discovery to meaningful diagnostics, today announced that they have expanded their alliance to develop and automate the analysis of new biomarker assays for clinical trials and routine clinical testing. Under the agreement, Definiens will provide automated quantitative biomarker solutions to support NeoGenomics’ immunohistochemistry services for both its Pharma Services customers and Clinical...

Read More

Apotex Announces $184 Million Investment to Grow U.S. Manufacturing Presence

Posted by on Mar 10, 2017 in Newsroom | 0 comments

BROWARD COUNTY, FL. – Apotex Inc., the largest Canadian owned pharmaceutical company, announced on March 8, 2017,  the details of a $184 million U.S. expansion plan, including the development of a new R&D center and advanced manufacturing and packaging facility that will serve as the U.S. headquarters for Apotex Corp. and the U.S. offices for Apobiologix. This move marks the largest investment that Apotex has made in the U.S. and will result in at least 150 new full-time positions. The company chose this strategic location to facilitate more efficient expansion and service of...

Read More

Pfizer commits $4M to NC Biotechnology Center gene therapy fellowship program

Posted by on Mar 1, 2017 in Newsroom | 0 comments

RALEIGH, N.C. – The North Carolina Biotechnology Center has announced that Pfizer has committed to providing funding  in the amount of $4 million which will enable the Center to establish and administer a  multi-year academic fellowship program to help advance North Carolina’s fast-growing expertise in gene therapy. The new program, to be managed by NCBiotech, will support distinguished postdoctoral fellowships in North Carolina university research laboratories providing advanced scientific training in gene therapy-related research. Absent or faulty proteins linked to genetic...

Read More

Vycellix and Moffitt Cancer Center Announce a Collaborative Research Study

Posted by on Feb 27, 2017 in Newsroom | 0 comments

SARASOTA and TAMPA, FL. – Vycellix, Inc., a biopharmaceutical company advancing innovative small molecules to enhance cellular therapies, facilitate manufacturing processes and optimize human immune response against disease, announced on February 27th, that it has entered into a collaborative research arrangement with Moffitt Cancer Center, an NCI Comprehensive Cancer Center, to further validate Vycellix’s novel product candidates, VY-OZ and VY-X. The planned studies aim to evaluate the molecules’ potential as a platform technology capable of enhancing the potency of adoptive cell...

Read More